Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a ...

Canaccord lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps a Buy rating on the shares. The firm said ...

March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were ...

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...

Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...

LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will ...

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago. These ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...

VOYAGER THERAPEUTICS ($VYGR) posted quarterly earnings results on Tuesday, March 11th. The company reported earnings of -$0.59 per share, missing estimates of -$0.37 ...

Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $34.5 million in its fourth quarter. On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 59 cents. The ...

Good afternoon, and welcome to Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a ...